参考文献/References:
[1] Ross R. Atherosclerosis—an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
[2] de Weerd M, Greving JP, Hedblad B, et al. Prevalence of asymptomatic carotid artery stenosis in the general population an individual participant data meta-analysis[J]. Stroke, 2010, 41(6): 1294-1297.
[3] Nagai Y, Kitagawa K, Sakaguchi M, et al. Significance of earlier carotid atherosclerosis for stroke subtypes[J]. Stroke, 2001, 32(8): 1780-1785.
[4] Hermus L, Lefrandt JD, Tio RA, et al. Carotid plaque formation and serum biomarkers[J]. Atherosclerosis, 2010, 213(1): 21-29.
[5] Norata GD, Ballantyne CM, Catapano AL. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a)lowering drugs[J]. Eur Heart J, 2013, 34(24): 1783-1789.
[6] Ammirati E, Bozzolo EP, Contri R, et al. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus[J]. Nutr Metab Cardiovasc Dis, 2014, 24(7): 751-759.
[7] Ammirati E, Moroni F, Magnoni M, et al. The role of T and B cells in human atherosclerosis and atherothrombosis[J]. Clin Exp Immunol, 2015, 179(2): 173-187.
[8] Sternberg Z, Ghanim H, Gillotti KM, et al. Flow cytometry and gene expression profiling of immune cells of the carotid plaque and peripheral blood[J]. Atherosclerosis, 2013, 229(2): 338-347.
[9] Halvorsen DS, Johnsen SH, Mathiesen EB, et al. The association between inflammatory markers and carotid atherosclerosis is sex dependent: the Troms Study[J]. Cerebrovasc Dis, 2009, 27(4): 392-397.
[10] Chapman CML, Beilby JP, McQuillan BM, et al. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis[J]. Stroke, 2004, 35(7): 1619-1624.
[11] Thiele JR, Habersberger J, Braig D, et al. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy[J]. Circulation, 2014, 130(1): 35-50.
[12] Stancel N, Chen CC, Ke LY, et al. Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis[J]. Clin Chem, 2016, 62(2): 320-327.
[13] Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis[J]. JAMA, 2005, 294(14): 1799-1809.
[14] Green D, Foiles N, Chan C, et al. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study[J]. Atherosclerosis, 2009, 202(2): 623-631.
[15] Lepedda AJ, Cigliano A, Cherchi GM, et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries[J]. Atherosclerosis, 2009, 203(1): 112-118.
[16] Borissoff JI, Spronk HMH, Ten CH. The hemostatic system as a modulator of atherosclerosis[J]. N Engl J Med, 2011, 364(18): 1746-1760.
[17] Debing E, Peeters E, Demanet C, et al. Markers of inflammation in patients with symptomatic and asymptomatic carotid artery stenosis: a case-control study[J]. Vasc Endovasc Surg, 2008, 42(2): 122-127.
[18] Pelisek J, Rudelius M, Zepper P, et al. Multiple biological predictors for vulnerable carotid lesions[J]. Cerebrovasc Dis, 2009, 28(6): 601-610.
[19] Kampoli AM, Tousoulis D, Papageorgiou N, et al. Matrix metalloproteinases in acute coronary syndromes: current perspectives[J]. Curr Top Med Chem, 2012, 12(10): 1192-1205.
[20] Abbas A, Aukrust P, Russell D, et al. Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis[J]. PLoS One, 2014, 9(1): e84935.
[21] Orbe J, Montero I, Rodriguez JA, et al. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis[J]. J Thromb Haemost, 2007, 5(1): 91-97.
[22] Puz P, Lasek-Bal A, Ziaja D, et al. Inflammatory markers in patients with internal carotid artery stenosis[J]. Arch Med Sci, 2013, 9(2): 254-260.
[23] Abbas A, Aukrust P, Dahl TB, et al. High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis[J]. Stroke, 2012, 43(5): 1347-1353.
[24] Sugioka K, Naruko T, Hozumi T, et al. Elevated levels of neopterin are associated with carotid plaques with complex morphology in patients with stable angina pectoris[J]. Atherosclerosis, 2010, 208(2): 524-530.
[25] Koutouzis M, Rallidis LS, Peros G, et al. Serum interleukin-6 is elevated in symptomatic carotid bifurcation disease[J]. Acta Neurol Scand, 2009, 119(2): 119-125.
[26] Garcia BA, Ruiz C, Chacon P, et al. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque[J]. J Vasc Surg, 2003, 38(5): 1018-1024.
[27] Holm S, Ueland T, Dahl TB, et al. Fatty acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke[J]. PLoS One, 2011, 6(12): e28785.
[28] Shindo A, Tanemura H, Yata K, et al. Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability[J]. PLoS One, 2014, 9(6): e100045.
[29] Edsfeldt A, Nitulescu M, Grufman H, et al. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque[J]. Stroke, 2012, 43(12): 3305-3312.
[30] Norata GD, Raselli S, Grigore L, et al. Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells[J]. Atherosclerosis, 2009, 206(2): 556-562.
[31] Martín-Ventura JL, Madrigal-Matute J, Muñoz-Garcia B, et al. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells[J]. Cardiovasc Res, 2009, 83(3): 586-594.
[32] Pelisek J, Well G, Reeps C, et al. Neovascularization and angiogenic factors in advanced human carotid artery stenosis[J]. Circ J, 2012, 76(5): 1274-1282.
[33] Jaipersad AS, Shantsila A, Lip GYH, et al. Expression of monocyte subsets and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis[J]. Ann Med, 2014, 46(7): 530-538.
[34] Camici PG, Rimoldi OE, Gaemperli O, et al. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque[J]. Eur Heart J, 2012, 33(11): 1309-1317.
[35] Ammirati E, Magnoni M, Camici PG. Need for new non-invasive imaging strategies to identify high-risk asymptomatic patients with carotid stenosis[J]. In J Cardiol, 2013, 168(4): 4342-4343.
[36] Ammirati E, Moroni F, Norata GD, et al. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis[J]. Mediators Inflamm,2015,2015:718329. doi:10.1155/2015/718329.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(3):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]阎萌,田芳,综述,等.程序性坏死与动脉粥样硬化[J].心血管病学进展,2016,(2):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
YAN Meng,TIAN Fang,TIAN Ye.Necroptosis and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(3):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
[3]陈芡茹,综述,叶飞,等.心血管疾病治疗新目标:脂蛋白相关磷脂酶A2[J].心血管病学进展,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
CHEN Qianru,YE Fei.Novel Therapeutic Target of Cardiovascular Disease:Lipoprotein Associated
Phospholipase A2[J].Advances in Cardiovascular Diseases,2016,(3):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
[4]杨娟,综述,王佑华,等.肠道菌群与血管内炎症[J].心血管病学进展,2016,(3):263.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.012]
YANG Juan,WANG Youhua,YUAN Suyun.Relationship Between Gut Microbiota and Vascular Inflammation[J].Advances in Cardiovascular Diseases,2016,(3):263.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.012]
[5]夏平,杨浩.炎症与心房颤动相关性的研究进展[J].心血管病学进展,2015,(5):637.[doi:10.3969/j.issn.1004-3934.2015.05.030]
XIA Ping,YANG Hao.Research Progress of Inflammation Associated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):637.[doi:10.3969/j.issn.1004-3934.2015.05.030]
[6]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(3):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[7]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(3):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[8]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(3):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[9]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(3):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[10]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(3):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]